Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses advances in the treatment of HER2-positive breast cancer.
Transcript:
Is there anything you’re working on or excited about in HER2-positive breast cancer that you’d like to share?
We're working on a number of different things. One is trying to move neratinib earlier in the adjuvant course and seeing if we can manage the diarrhea with a novel agent. So that’s one trial my colleague Joe Chen is working on.
In terms of the metastatic setting, there are a number of novel agents, oral TKIs [tyrosine-kinase inhibitors], and then an antibody—drug conjugate from Daiichi which has shown responses in patients who had highly resistant disease, at least as reported to trastuzumab. That’s going into a phase 3 trial this year. Then there’s a novel antibody that binds to the receptors a bit differently called margetuximab that’s in a phase 3 trial called the SOPHIA trial. That drug also showed responses in phase 1 studies in patients who had disease resistant to trastuzumab.
So, I think there’s a number of different agents out there which seem as though they have potential for the future.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.